FDA Grants Orphan Drug Designation to AFM13 for the Treatment of T-cell Lymphoma
The U.S. Food and Drug Administration has granted orphan drug designation to AFM13 for the treatment of patients with T-cell lymphoma, according to a press release. The designation includes peripheral T cell lymphoma (pTCL), a subtype of T-cell lymphoma.
AFM13 is currently being investigated in a Phase 2 registration-directed study.
Read the full press release here.